- IPC GENERAL
- Drug Approvals, Industry, Treatment
Dermavant Sciences announced that VTAMA® (tapinarof) cream, 1%, an aryl hydrocarbon receptor agonist, indicated for the topical treatment of plaque psoriasis in adults, has been approved by the U.S. Food and Drug Administration (FDA). VTAMA® cream provides efficacy over 52 weeks and is well-tolerated on the most sensitive skin areas. This approval makes VTAMA® cream the first and only FDA-approved non-steroid topical medication for adults living with plaque psoriasis. The product is expected to be available beginning June 2022.
